Phase 3 Clinical Trials With Primary Completion Dates in May 2017
This is a list of Phase 3 trials with primary completion dates in May 2017 for companies with a market cap less than $1B. For complete clinical trial coverage, please see our Trial Tracker tool. It includes information on all clinical trials for publicly traded companies, screenable by stock symbol, market cap, disease, completion date, and phase.
The primary completion date is the date that the final subject was examined or received an intervention for the purposes of final collection of data for the primary outcome. It provides advance notice that a company will be announcing trial results in the near future.
| Symbol | Company | Primary Completion Date | Phase | NCT ID | Title |
|---|---|---|---|---|---|
| ACOR | Acorda Therapeutics, Inc. | 2017-05-01 | Phase 3 | NCT02352363 | Randomized Safety Study of CVT-301 Compared to an Observational Control Group |
| ENDP | Endo International plc | 2017-05-01 | Phase 3 | NCT01784848 | GAstric Bypass to Treat obEse Patients With steAdy hYpertension |
| MMSI | Merit Medical Systems, Inc. | 2017-05-01 | Phase 3 | NCT01789840 | Prostate Artery Embolization With Embosphere Microspheres Compared to TURP for Benign Prostatic Hyperplasia |
| NURO | NeuroMetrix, Inc. | 2017-05-01 | Phase 3 | NCT02809846 | Quell Opioid Reduction and Pain Relief in Patients With Cancer |
| PBYI | Puma Biotechnology Inc | 2017-05-01 | Phase 3 | NCT01808573 | A Study of Neratinib Plus Capecitabine Versus Lapatinib Plus Capecitabine in Patients With HER2+ Metastatic Breast Cancer Who Have Received Two or More Prior HER2 Directed Regimens in the Metastatic Setting |
| PODD | Insulet Corporation | 2017-05-01 | Phase 3 | NCT02561078 | An Administration Method Study of Human Regular U-500 Insulin (LY041001) in Participants With Type 2 Diabetes Mellitus |
| PRTK | Paratek Pharmaceuticals, Inc. | 2017-05-01 | Phase 3 | NCT02877927 | Oral Omadacycline vs. Oral Linezolid for the Treatment of ABSSSI |
| SUPN | Supernus Pharmaceuticals, Inc. | 2017-05-01 | Phase 3 | NCT02618434 | Treatment of Impulsive Aggression in Subjects With ADHD in Conjunction With Standard ADHD Treatment (CHIME 2) |
| TBPH | Theravance Biopharma, Inc. | 2017-05-01 | Phase 3 | NCT02518139 | A 52-Week Parallel Group Safety Study of TD-4208 in Chronic Obstructive Pulmonary Disease (COPD) |
| XBIT | XBiotech Inc. | 2017-05-01 | Phase 3 | NCT01767857 | A Phase III Study of Xilonix in Patients With Advanced Colorectal Cancer |